In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …

Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

The hormone receptor oestrogen receptor-α (ER) orchestrates physiological mammary
gland development, breast carcinogenesis and the progression of breast tumours into lethal …

Endocrine therapy (ET) is a pivotal strategy to manage early-and advanced-stage estrogen
receptor-positive (ER+) breast cancer. In patients with metastatic breast cancer (MBC) …

The importance and role of the estrogen receptor (ER) pathway has been well-documented
in both breast cancer (BC) development and progression. The treatment of choice in women …

Breast cancers with positive expression of Estrogen Receptor (ER+) are treated with anti-
hormone/endocrine therapy which targets the activity of the receptor, the half-life of the …

Abstract Estrogen receptor-positive (ER+) breast cancer accounts for approximately 75% of
all breast cancers. Endocrine therapies, including selective ER modulators (SERMs) …

Introduction The majority of breast cancers (BCs) are characterized by the expression of
estrogen receptor alpha (ERα+). ERα acts as ligand-dependent transcription factor for genes …

Introduction The selective estrogen receptor degrader (SERD) and full receptor antagonist
provides an important therapeutic option for hormone receptor (HR)-positive breast cancer …

Highlights•Endocrine resistance represents one of the major causes of breast cancer
mortality.•PI3K/AKT/mTOR pathway resulted in increased ER expression.•CyclinD1-CDK4/6 …